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The axis comprised by the Vasoactive Intestinal Peptide (VIP) and its G protein-coupled
receptors (GPCRs), VPAC1, and VPAC2, belong to the B1 family and signal through Gs
or Gq proteins. VPAC receptors seem to preferentially interact with Gs in inflammatory
cells, rather than Gq, thereby stimulating adenylate cyclase activity. cAMP is able to
trigger various downstream pathways, mainly the canonical PKA pathway and the
non-canonical cAMP-activated guanine nucleotide exchange factor (EPAC) pathway.
Classically, the presence of VPACs has been confined to the plasmamembrane; however,
VPAC1 location has been described in the nuclear membrane in several cell types
such as activated Th cells, where they are also functional. VPAC receptor signaling
modulates a number of biological processes by tipping the balance of inflammatory
mediators in macrophages and other innate immune cells, modifying the expression
of TLRs, and inhibiting MMPs and the expression of adhesion molecules. Receptor
signaling also downregulates coagulation factors and acute-phase proteins, promotes
Th2 over Th1, stimulates Treg abundance, and finally inhibits a pathogenic Th17 profile.
Thus, the VIP axis signaling regulates both the innate and adaptive immune responses
in several inflammatory/autoimmune diseases. Rheumatoid arthritis (RA) is a complex
autoimmune disease that develops on a substrate of genetically susceptible individuals
and under the influence of environmental factors, as well as epigenetic mechanisms. It is a
heterogeneous disease with different pathogenic mechanisms and variable clinical forms
between patients with the same diagnosis. The knowledge of VIP signaling generated in
both animal models and human ex vivo studies can potentially be translated to clinical
reality. Most recently, the beneficial effects of nanoparticles of VIP self-associated with
sterically stabilized micelles have been reported in a murine model of RA. Another
novel research area is beginning to define the receptors as biomarkers in RA, with
their expression levels shown to be associated with the activity of the disease and
patients-reported impairment. Therefore, VPAC expression together VIP genetic variants
could allow patients to be stratified at the beginning of the disease with the purpose of
guiding personalized treatment decisions.
Keywords: VPAC receptors, vasoactive intestinal peptide, rheumatoid arthritis, inflammation, autoimmunity,
prognosis biomarker
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune disease that
causes joint inflammation and cartilage and bone destruction.
RA affects 1% of the population worldwide and it is associated
with damage of physical condition and quality of life. RA
progresses in genetically susceptible individuals, under the effect
of environmental factors, as well as with the contribution of
epigenetic mechanisms. Vasoactive Intestinal Peptide (VIP) and
its G protein-coupled receptors (GPCRs), VPAC1, and VPAC2,
shape an axis signaling that regulates both the innate and immune
response in several inflammatory/autoimmune diseases.
In the following sections, we will describe its therapeutic role
in animal models of RA and its potential as a biomarker for the
stratification of patients, contributing to the improvement of the
development of personalized therapies.




VIP is a broadly distributed neuropeptide with known
immunomodulatory attributes. VIP can act through three
receptors: VIP acts almost exclusively through two high affinity
receptors: VPAC1 and VPAC2. A third receptor, PAC1, poorly
binds VIP in most physiological contexts, acting primarily by
binding to the related ligand PACAP. In RA, VIP expression
has been reported in nerve endings and in other cell types in
the inflamed area, and it has been shown to actively modulate
immune responses in experimental arthritis. In this regard,
VIP released from sensory axonal terminals interacts with
other molecules produced by nearby neutrophils, macrophages,
and other immune and endothelial cells (1). Lymphocytes
and synovial fibroblasts (SF) also produced and released VIP
(2–5).VPAC1 and VPAC2 belong to the B1 family of GPCRs.
PAC1, along with the secretin receptor, the glucagon receptor,
the parathyroid hormone receptors and several others, are
also found in this family. The members of this GPCR family
share some specific characteristics (6, 7): (i) the presence of a
large N-terminal ectodomain containing six highly conserved
cysteine residues connected by three disulfide bridges; (ii) the
N-terminal acting as the major binding site for its natural peptide
ligand; (iii) the existence of a signal peptide; (iv) the presence
of N-glycosylation sites; (v) the lack of archetypical family A
GPCR motifs such as E/D-R-Y or NP-xx(x)-Y; and (vi) the
presence of many introns in their gene organization. This last
point indicates that alternative splicing events could arise within
VPAC receptors, however, although there is some evidence
for the presence of splice variants of the VPAC1 and VPAC2
receptors, their functional significance is not yet clear (8). Studies
with CHO cell line indicate that these receptors can also form
oligomeric complexes, like other GRPRs, VPAC1 receptor is
able to homodimerize and heterodimerize with VPAC2 or the
secretin receptor (9). This oligomerization does not affect the
recognition of ligands nor the function of the receptors (10).
It has been proposed that the interaction between natural
ligands and VPAC receptors follows the “two-site” model, in the
same way as in other members of the B1 family (6, 7). In this
model, the central and C-terminal parts of the peptide ligand are
trapped by the N-terminal of the receptor, which ensures correct
ligand positioning. Binding of residues 1–6 of the ligand to the
extracellular loops and transmembrane helices leads to receptor
activation. To determine this, most studies have used VIP as the
natural ligand and VPAC1 as the receptor (11, 12).
VPAC receptors signal through Gs or Gq proteins, class B
receptors in general demonstrate greater potency in cAMP than
IP3 generation, but this depends on cell type. In inflammatory
cells, VPAC have greater affinity for Gαs than Gαq, indicating
that VPAC receptors preferentially stimulate adenylyl cyclase
activity. In addition, it has been demonstrated in cell lines
that these receptors can also interact with non-G proteins,
which are termed “accessory proteins” or “GPCR interacting
proteins (GIPs),” such as RAMPs or PDZ-containing proteins
(6, 7, 13, 14). This interaction can modulate several properties
of VPAC receptors including their ability to interact with G
proteins or their agonist-induced internalization. As mentioned
above, adenylyl cyclase activation and the subsequent increase in
cAMP levels is the main signaling pathway of VPAC receptors.
However, cAMP is able to trigger various downstream pathways,
mainly the canonical PKA pathway and the non-canonical
cAMP-activated guanine nucleotide exchange factor (EPAC)
pathway. Depending on the cell type, EPAC and PKA may
act independently, synergistically, or may oppose each other
regulating specific cellular functions (15). In addition to the PKA-
dependent pathway, it has been shown that VPAC receptors
can also activate the PKA-independent pathway in several cell
types (16, 17). On the other hand, binding of Gαq to VPAC is
involved in the activation of the phospholipase C (PLC) pathway,
stimulating protein kinase C (PKC) and promoting release of
Ca2+ from the endoplasmic reticulum [(8, 10); Figure 1].
VPAC receptors, as with other GPCRs, are synthesized by the
protein secretory pathway and their expression and trafficking
are under co- and post-translational quality control to ensure
that only proper VPAC receptors reach the cell surface (24).
These receptors can also undergo internalization by homologous
or heterologous desensitization (25, 26). In regards to the
VPAC1 receptor, the internalization from plasma membrane by
endosomes is induced by its own ligand, VIP. In addition to
the plasma or endosome membranes, the intracellular position
of functional GPCRs now broadly accepted by the scientific
community (27, 28). The presence of VPAC1 receptor has been
described in intracellular compartments, such as the nuclear
membrane in different cells, as human breast cell lines, glioma
cell lines or activated ex vivo Th lymphocytes, where they are also
functional (17, 29–31). In this sense, the palmitoylation of the N-
terminal extracellular Cys37 of the VPAC1 receptor induced by
VIP mediates the nuclear translocation of this receptor (31). The
trafficking of the VPAC1 receptor from the plasma membrane
to the nuclear membrane could be related to the fact that the
peptide sequence of this receptor has a nuclear localization signal
sequence in its intracytoplasmic C-terminal, not found in the
VPAC2 receptor (30). In this sense, the presence of VPAC2
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FIGURE 1 | Functional consequences of VPAC receptors signaling. VIP binds both, VPAC1 and VPAC2. VPAC receptors have greater affinity for Gαs than Gαq,
indicating that VPAC receptors preferentially stimulate adenylyl cyclase (AC) activity, increasing cAMP levels and triggering downstream pathways, mainly the canonical
PKA pathway and the non-canonical cAMP-activated guanine nucleotide exchange factor (EPAC) pathway. Moreover, these receptors can also interact with accessory
(Continued)
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FIGURE 1 | GPCR interacting proteins (GIPs), such as RAMPs or PDZ-containing proteins (PDZ-cp). In addition, VPAC1 is also able to translocate to nucleus.
Activation of VPAC receptors signaling modulates a number of biological processes, which eventually lead to the decrease of the inflammation, cartilage destruction
and bone erosion. In relation to the clinical application, it has been reported the beneficial effects of nanoparticles of VIP self-associated with sterically stabilized
micelles (SSMs) in collagen-induced arthritis (CIA) murine model (18, 19) and DSS induced colitis (20). We have also demonstrated the prognosis value of VIP serum
levels and VIP genetic variants. Moreover, VPAC receptors expression has been described as activity biomarkers associated with patients-reported impairment
(21–23).
in intracellular locations other than endosomes has not yet
been described.
The development of selective agonists or antagonists for
GPCR is essential for studying these receptors, both from
research and pharmacological points of view. These molecules
must possess ligand-selectivity, cross-species reactivity and
receptor subtype selectivity. Different VPAC receptor agonists
and antagonists have been developed over the years, however,
only a few of them have all these characteristics and are
broadly recognized by the scientific community. Thus far,
there are two selective agonists for the VPAC1 receptor,
[Ala11,22,28]VIP (32) and [Lys15, Arg16, Leu27]VIP (1–7)/CRF
(8–17, 24–33). A molecule derived from this agonist, AcHis1
[DPhe2, Lys15, Arg16, Leu27]VIP (1–7)/CRF (8–17, 24–33), also
called PG97-269, is currently the only selective antagonist for
the VPAC1 receptor (34). Ro 25-1553 and Ro 25-1392 are
the only selective agonists for the VPAC2 receptor described
thus far (35, 36). An artificial VPAC2 receptor antagonist, the
cyclic peptide VIPpep-3 (Ac-CPPYLPRLCTLLLRS-OH), which
has the characteristics abovementioned for a good antagonist,
has recently been described (37). Studies with VPAC1 and
VPAC2 chimeric receptors have shown that different agonists or
selective antagonists of these receptors require interactions with
different domains in the receptors to generate their selectivity
(38). For example, the N-terminal extracellular domain is
responsible for the selectivity of the PG97-269 VPAC1 antagonist,
whereas the selective recognition of the VPAC1 agonist, [Lys15,
Arg16, Leu27]VIP (1–7)/CRF (8–17, 24–33), is supported by a
large receptor area, namely the N-terminal domain, the first
extracellular loop, and additional determinants in the distal
part of this receptor (39). Moreover, new delivery strategies
are being developed to improve the potency, selectivity and
pharmacokinetics of VIP. The most striking development is
nanotechnology, which provides a VIP-controlled drug delivery,
avoiding the peptide breakdown by proteases and digestive acids
before it reaches its target (40).
In light of this, we could consider that the traditional point
of view, in which cell surface GPCRs are the only targets
for therapeutic beneficial drugs or for studying their signaling
pathways and functional consequences, is incomplete. Upon
activation at the cell surface, many GPCRs with their agonists
traffic through intracellular compartments like endosomes or the
nucleus, where they can continue to signal. VPAC receptors are
no different from other GPCRs, and thus, it is important to define
what functions are exerted by these receptors, depending on their
location in the cell. It is necessary to develop better techniques
to reveal the molecular details of signaling by unmodified VPAC
receptors and their spectrum of signaling and regulatory partners
in subcellular microdomains of functionally relevant cells in
real time (41). Approaches such as cryoelectron tomography,
which can provide structural information about protein signaling
complexes in intact cells, or GPCR ascorbate peroxidase (GPCR-
APEX), which can be used for the identification of proteins
that are closely associated with GPCRs by mass spectrometry,
will be very useful (41). In addition, it is necessary to develop
VPAC receptor agonists or antagonists that specifically target
intracellular VPAC receptors to achievemore specificmodulation
of their physiological responses.
VIP/VPAC AXIS IN ANIMAL MODELS OF
RHEUMATOID ARTHRITIS
Collagen-induced arthritis (CIA) is a model that can be induced
in mice, rats or primates. It shares different features with RA,
as immunization of animals with type II collagen leads to a
chronic, destructive polyarthritis (42) and thus, this model is
widely used to study the mechanisms involved in this disease. In
2001, Delgado and colleagues described for the first time howVIP
treatment of CIA mice improves the progression of the disease,
reducing the incidence and severity of arthritis and avoiding joint
swelling and destruction of cartilage and bone (43). Mice treated
with VIP daily were best protected from the disease, although a
single administration at the onset of CIA was enough to decrease
the severity. The mechanisms underlying the improvement
of the disease are immunomodulatory as VIP regulates T
helper (Th1/Th2 balance, diminishing Th1 and augmenting Th2
cytokines and cells, and it decreases the T helper: T suppressor
ratio. Moreover, VIP also affects the inflammatory components
of the disease, as VIP treatment downregulates numerous pro-
inflammatory factors, as well as several chemokines while it
increases anti-inflammatory cytokines. Furthermore, VIP also
affects the inflammatory components of the disease, as VIP
treatment downregulates numerous pro-inflammatory factors, as
well as several chemokines while it increases anti-inflammatory
cytokines. Moreover, VIP decreases the expression and activity
of matrix metalloproteinases, therefore inhibiting cartilage
destruction and bone erosion. The main receptor involved in
VIP effects on arthritis is VPAC1, as demonstrated by the use
of specific agonists in arthritic mice (43). VIP inhibits the LPS-
induced release of cytokines involved in the production of pro-
inflammatory mediators in CIA rats, and reduces the TNFα-
induced proliferation of synovial cells by downregulating the
enhanced expression and activity of NFκB transcription factor.
Moreover, the use of a VPAC antagonist counteracts the effect of
VIP (44).
Some studies have corroborated the anti-inflammatory role of
VIP in the CIA mice model, deepening our understanding of the
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pathways, receptors, and cell types involved. For instance, VIP
is able to diminish the expression of inflammatory mediators
and cytokines related to bone destruction, while enhancing the
expression of those related to bone protection by means of NFκB
and Jun N-terminal kinase pathways (45). Moreover, a selective
VPAC1 agonist is able to reduce the chronic inflammation of
synovial tissue, the expression of inflammatory cytokines and
chemokines, cartilage destruction, and bone erosion, whereas
the selective VPAC2 agonist is not (46). Synovial cells are the
major producers of innate immune inflammatory mediators, but
dendritic cells (DCs) are also able to produce these mediators,
driving, at least in part, inflammation in RA. In this regard, a
recent study showed that DCs differentiated from monocytes
in the presence of VIP are tolerogenic DCs which, when
administrated to CIA mice, reduce the arthritic scores (47).
Studies in the CIA rat model demonstrate that VIP reduces
the severity of the disease by regulating the balance of Th1/Th2,
enhancing regulatory T cells (Treg) and reducing Th17 cells,
modulating the mediators of bone erosion (48, 49). Moreover,
the expression of the three VIP receptors on osteoclasts is
downregulated with the onset of the disease in this model, and
VIP diminishes the activity of these bone-related cells (50).
VPAC1 expression is shown to be downregulated in synovial
tissue of CIA rats and is enhanced by electroacupuncture
treatment while VPAC2 remains the same (51). In the most
recent paper published thus far, the authors hypothesized that
VIP downregulates the CIA ratmodel by virtue of the enrichment
of regulatory monocytes (52).
Given the short half-life of this peptide, some attempts have
been made to achieve better targeting to inflammation sites of
VIP, with lower doses required, such as viral and non-viral vectors
to deliver VIP by gene therapy, the generation of latent forms
of this peptide by fusion to latency-associated peptides, or the
administration of VIP inside stabilized micelles. All of these
innovative forms of delivery have been assayed in the CIA model
of rheumatoid arthritis (18, 53, 54).
Other models that have been very useful in the study
of the VIP/VPAC axis are the genetically modified mice,
knockout mice, which have served to better understand the
involvement of endogenously produced VIP. Mice lacking
VIP gene by homologous recombination, were able to survive
to weaning, despite the wide distribution of this peptide in
the organism, but with important alterations in circadian
rhythms (55). Moreover, VIP KO mice exhibit changes in
reproductive function, behavior, feeding, metabolism, bladder
function and gastrointestinal tract as it has been recently
reviewed (56). PACAP, VPAC1, VPAC2, and PAC1 knockout
mice have also been developed which has served to identify
the involvement of these receptors in different physiological
processes (56). All these KO models have shown normal basal
immune characteristics, although when subjected to immune
diseases models, they exhibited impaired immune responses. For
instance, VIP KO developedmore severe dinitrobenzene sulfonic
acid (DNBS)-induced colitis, exacerbated inflammatory asthma
and enhancement of innate and adaptive immune responses
in a model of viral infection than wild-type mice. However,
opposing effects in several inflammatory/autoimmune models
developed in VIP KO mice such as LPS-induced endotoxemia,
TNBS- and DSS induced-colitis and experimental autoimmune
encephalomyelitis (EAE), a model for multiple sclerosis, have
been reported (57–59). To date, there is no clear explanation
for these results and different hypotheses have emerged that
should be verified. Among others, it has been proposed that
under some conditions the involvement of VIP could be essential
for the whole expansion of immune responses. The existence
of compensatory mechanisms by PACAP and the involvement
of microbiota have also been suggested (56). VPAC1 KO mice
showed diminished inflammatory responses in DNBS-induced
colitis and a resistant phenotype to EAE. Besides, VPAC2 KO
mice were subjected to skin immediate-type (ITH) and delayed-
type (DTH) hypersensitivity models and showed enhanced DTH
with augmented Th1 but reduced Th2 cytokine generation
and reduced ITH, suggesting a protective role of this receptor
against Th1-driven diseases, furthermore, VPAC2 KO mice
exhibited exacerbated EAE compared to wild-type mice (56).
Unfortunately, as far as we know, there are no studies carried out
with the CIA model in mice deficient of VIP, which could serve
to corroborate the data described above.
VPAC RECEPTORS SIGNALING CONTROL
IMMUNE RESPONSE IN HEALTHY AND RA
PATIENTS
Immune dysregulation is at the core of RA pathogenesis,
implying disordered immune responses at both systemic and
local levels. Furthermore, joints affected by RA characteristically
exhibit an altered hyper-activation state of the synovial stromal
tissue, which also plays a critical role in the joint pathology.
During RA progression, the synovial lining layer expands up to
10–12 cells in thickness, comprised of both SF and macrophages,
and the sublining is infiltrated by adaptive and innate immune
cells, including B and T lymphocytes as well as inflammatory
monocytes, which will differentiate into macrophages (60).
Synovial Fibroblasts
Joint resident RA synovial fibroblasts (RASF) are mesenchymal
stromal cells with immunomodulatory capabilities that secrete
cytokines, chemokines and matrix damaging enzymes, actively
contributing to synovitis, and ultimately, to cartilage/bone
destruction (61, 62). RASF assume an autonomous pathogenic
phenotype characterized by the capacity for hyperproliferation
and migration, which contributes to the synovium hyperplasia
and to the spread of the disease to unaffected joints (63).
The pathogenic behavior of RASF is activated and enhanced
in response to multiple pathways, including pro-inflammatory
mediators and Toll-like receptor (TLR) ligands present in the RA
synovium (64).
VIP anti-inflammatory signaling is functional in RASF,
decreasing the production of pro-inflammatory cytokines and
chemokines (65), also showing immunomodulatory effects on
TLR2 and TLR4 through a negative regulation of their expression
and function (66). Moreover, VIP exerts an inhibitory action over
several RNA sensors involved in the activation of RASF, including
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TLR3, TLR7 and helicases RIG-I and MDA-5 (67). VIP is also
able to counterbalance the enhancing effect of pro-inflammatory
molecules on the expression of IL-17 receptors by RASF and
on their production of IL-12 and IL-23 cytokines, which are
involved in the facilitation of Th1 and Th17 differentiation,
respectively (68).
Effects of VIP on RASF are mediated by its receptors, VPAC1
and VPAC2, which exhibit a differential expression pattern when
compared to osteoarthritis (OA) SF. VPAC2 is the dominant
receptor in RASF whereas VPAC1 is preferentially detected
in OASF, with no presence of PAC1 receptor in either type
of SF (4, 69). It is worth noting that TNFα-treated OASF
adopt a pattern of expression for VPAC receptors equivalent
to RA, suggesting a modulatory effect of the pro-inflammatory
synovial milieu on the VPAC system. The functional activity
of VPAC receptors in OA and RASF is coupled to adenylate
cyclase (AC), and specific agonists for each receptor subtype are
equivalent to VIP in inducing an increase in intracellular cAMP
levels by activating the dominant receptor, VPAC1 and VPAC2,
respectively. Specifically, the VPAC2-specifc agonist reproduces
the inhibitory effects of VIP on pro-inflammatory CXCL8, IL-
6 and CCL2 production by RASF (4). Therefore, VPAC2 is the
receptor mediating the immunomodulatory effects of VIP on
RASF through the activation of the AC pathway.
Monocytes/Macrophages
RA synovial macrophages are considered central effectors in
the progression of joint degeneration, by secreting several pro-
inflammatory cytokines and joint-damaging mediators (70). In
fact, pathological contribution of SF to RA progression is directly
linked to both resident and monocyte-derived infiltrating
macrophages (71, 72). The number of synovial sublining
macrophages is correlated with the degree of joint erosion and
disease activity in RA patients (73). Specifically, RA synovial
macrophages exhibit a transcriptomic and protein profile that
is similar to that of macrophages polarized in vitro by GM-CSF
(GM-MØ), also known as M1. GM-MØ are characterized by
the expression and secretion of pro-inflammatory factors
in contrast to macrophages polarized by M-CSF (M-
MØ), also known as M2, that display an anti-inflammatory
profile (74).
Most studies demonstrate that VPAC1 is constitutively
expressed at higher levels than VPAC2 in resting human
monocytes/macrophages, whereas VPAC2 expression is induced
by immune stimulation (75–78). Other authors have described
the expression of PAC1 and the absence of VPAC2 in these cells,
probably as a result of the different methods used (77–79). More
recently, the analysis of VPAC receptors expression during the
time course of the in vitro polarization of monocytes toward
GM-MØ or M-MØ showed a progressive down-regulation of
transcripts for VPAC1 and VPAC2, detecting higher levels
for both receptors in GM-MØ at the end of the process.
Likewise, RA synovial macrophages, according to their GM-CSF-
like polarization state, exhibited a higher expression of VPAC1
and VPAC2 compared to macrophages from a non-inflamed
synovium (78).
Regarding the functional activity of VPAC receptors in
human monocytes, inhibitory signals of the VPAC2-specific
agonist on LPS-induced synthesis of TNFα and IL-12 have
been described (75). Likewise, VIP is able to reduce the
synthesis of TNFα, IL-6, and IL-12 by in vitro-generated GM-
MØ stimulated with LPS. In this regard, specific agonists
for VPAC receptors induce an increase in intracellular cAMP
levels in GM-MØ, with the VPAC1 agonist reaching levels
comparable to those induced by VIP. Moreover, the presence
of either VPAC1 or VPAC2 agonists during the GM-CSF-
driven in vitro polarization impairs the expression of GM-MØ-
specific gene markers and up-regulates some genes linked to
M-MØ, changing the macrophage profile to a less-damaging
phenotype (78).
Helper T Cells (Th) Cells
Naïve CD4+ Th cells can differentiate into several effector
subsets called Th1, Th2, Th17, Th9, Th22 or follicular helper
T (Tfh), and Treg. The differentiation of these subsets is
coordinated by complex regulatory networks that allow for
shared transcriptional programs and plasticity across T cell
subsets (80, 81). Effector Th cells (Th1, Th2, Th17, Th9, Th22,
Tfh) are important for protective immunity and Treg are
responsible for the tolerance of the immune system, however
some of these subsets have been related to a greater or lesser
extent with malfunctions of the immune system, specifically
autoimmune diseases, like RA (82, 83). Before the discovery
of Th17, RA was thought to be due to an increase in the
Th1 subset and a loss of tolerance, Treg. Nowadays, Th17 cells
have acquired a key role in the pathogenesis of RA (82–85).
This subset is heterogenic and can show a pathogenic or non-
pathogenic profile, depending on the cytokine balance present
in the microenvironment during its differentiation/activation.
In addition, Th17 cells are the most plastic subset of all the
others. Pathogenic Th17 cells are directly involved in RA and
are able to change their lineage commitment, shifting to Th1
cells (termed “non-classical Th1” cells or “Th17/1” cells), which
are reported to be more pathogenic than Th17 cells per se
in RA (84–87).
As stated above, in the animal model of RA, the CIA model,
VIP is able to rebalance Th1/Th2 subsets in the immune
system, decreasing Th1 cells and increasing Th2 cells, and
to downregulate Th17 responses. Furthermore, VIP also
expands Treg cells in the periphery in this animal model, which
inhibits autoreactive T cell activation/expansion, for example
increasing Treg/Th17 balance (43, 48, 88, 89). In peripheral
blood lymphocytes of RA patients cultured ex vivo, VIP favors
the Th2/Treg profile (90). In addition, VIP reduces the Th17
and Th17/1 pathogen profile of memory Th cells of early RA
patients activated/expanded ex vivo (89, 91). Even when memory
Th cells from early RA patients are polarized in vitro to a
non-pathogenic Th17 profile in the presence of TGFβ, they
maintain a pathogenic profile (92). However, the presence of
VIP during this Th17 polarization, increases their Treg/Th17
profile, characteristic of non-pathogenic Th17 cells, and
decreases the Th17/Th1 profile, characteristic of the pathogenic
phenotype (89, 92).
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Th cell activation induces changes in the expression of VPAC
receptors and their cellular location (17, 79, 86, 89, 91–93). Th
lymphocytes from mouse and human express both VPAC1 and
VPAC2 receptors and their mRNA expression patterns change
between Th cells from mouse, healthy donors and patients with
early RA. Activation of Th cells results in a loss of VPAC1 mRNA
expression, the range of expression of VPAC1 is between 11- and
61-fold higher in resting Th cells than activated cells, however
no changes at the protein level are detected in Th cells from
healthy donors or from early RA patients (17, 79, 89, 91). The
VPAC2 mRNA and protein expression is up-regulated after in
vitro activation, whereas low levels of VPAC2 are present in
resting Th cells, the range of expression is between 2- and 5-
fold higher in activated Th cells than resting cells (17, 79, 89).
In relation to their cellular location changes, in resting Th cells,
VPAC1 is found both on the cell surface and intracellularly,
whereas when these cells are activated, this receptor is found
exclusively inside the cell. This change in the receptor cellular
location is not observed for VPAC2 since it is always on the
cellular surface, regardless of the activation state of Th cells
(17). As early as Goetzl (94) hypothesized that VPAC receptors
constitute a dynamic system for signaling in T cells, predicting
that responses in the plasma membrane location would have a
fast onset and brief duration, whereas receptors in the nuclear
membrane would have responses with slow onset, sustained
in time (94). This fact is reflected in the signaling pathways
that these receptors trigger, as they signal through a PKA-
dependent pathway in resting or activated Th cells, and also by
a PKA-independent pathway in activated cells (17). In this way,
both receptors exhibit a potent immunomodulatory capacity by
controlling the pathogenic profile and the activation markers of
Th cells.
As it is above mentioned, the implication of Th1 cells was
initially ascribed to RA, however the discovery of the Th17
subset indicated a central role for these cells in this pathology.
VIP is able to modulate the differentiation and polarization
of these subsets in cells from RA patients. Thus, changes in
the pattern expression of VPAC are also important for the
pathology. In this context, the differentiation/polarization of
Th cells also induces changes in the expression of VPAC
receptors; for example, the differentiation/polarization toward
Th17 profile induces an increase in the VPAC2/VPAC1 ratio,
for example, 18-fold in Th17-differentiated cells from naïve
Th cells (86, 92). During the process of differentiation toward
a non-pathogenic Th17 profile, VPAC receptors have shown
different roles in regulating the production of inflammatory
mediators (86).
When VPAC receptor expression in Th cells from healthy
donors is compared with that of patients with early RA, the
VPAC2/VPAC1 ratio is 2.8-fold higher in cells from early RA
patients (17, 91, 92). These data perfectly correlate with the VPAC
receptor expression in PBMCs from early RA patients as we
described. Briefly, there is a loss of VPAC1mRNA expression and
an increase in VPAC2 expression in these patients (23). We can
conclude that VIP is a beneficial modulator that counterbalances
the different Th subsets and underscores the importance of VPAC
expression in RA.
CLINICAL SIGNIFICANCE OF VIP AND
VPAC RECEPTORS
Could VIP Be Useful as a Drug?
The knowledge generated in animal models and in human ex
vivo studies related to VIP and its signaling pathways could be
translated to clinical reality as two potential tools: as a therapeutic
agent and as a biomarker in inflammatory/autoimmune diseases.
Although RA disease has no cure, in the last two decades,
rheumatologists through an early diagnosis and rapid initiation
of an effective therapy are achieving disease remission or at least
significantly reducing the activity of the disease.
The present management strategy of RA, accepted by ACR,
EULAR, and the Asia Pacific League of Associations for
Rheumatology, is the “treat to target” method, which is based on
the strict control of the disease activity and the modification of
the treatment if the goal is not achieved (95–97).
The currently used therapeutic strategies include the non-
steroidal anti-inflammatory drugs (NSAIDs) as symptomatic
agents, glucocorticoids used for prevention of joint destruction,
and the disease-modifying anti-rheumatic drugs (DMARDs).
DMARDs comprise both synthetic (conventional drugs such
as methotrexate and targeted synthetic drugs such as JAK
inhibitors) and biological agents designed for the specific
inhibition of molecules of the immune system, such as TNF, IL-
6, IL-6 receptor, CD80-CD86, and CD20. The best results are
being achieved with the combined therapy of biological agents
and methotrexate. This approach to RA remission produces
an improvement of the physical function and prevention of
evolution of joint damage. Nevertheless, many patients fail to
decrease disease activity and advances in the development of new
or complementary therapies are still required (98).
An efficient translation of preclinical studies to the field of
health for the use of VIP as a therapeutic agent faces two
important challenges. On the one hand, it has low metabolic
stability with a short in vivo half-life, due to its degradation by
proteases, by spontaneous hydrolysis or by catalytic antibodies
(54). On the other hand, the systemic administration of VIP
can cause side effects due to the cross-interactions of binding
to three GPCRs, its functional pleiotropism and its ubiquity.
Severe decreases of the blood pressure, and alterations in the
cardiovascular and gastrointestinal system such as the watery
diarrhea syndrome (99, 100), have been documented. Thus,
VIP-mediated therapeutic intervention in RA management must
include the design of distribution systems directed against
specific targets and the protection of the peptide against its
degradation. Unfortunately, none of the strategies designed, such
as the use of VIP analogs or the application of protease inhibitors,
have rendered effects for use in systemic therapy.
With this background, the field of nanoparticle engineering
has been developed over the last few years, generating attractive
data, although not yet sufficient, for clinical application (40). Two
strategies have been developed with VIP-based nanoparticles:
(a) to act itself as a drug by means of encapsulation or by its
attachment to the surface of the nanoparticle; or (b) to serve
as a vehicle for another compound to a precise location. In
this second strategy, phospholipid nanomicelles spliced with VIP
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target acting as carriers for water-insoluble anticancer drugs
has been used in breast cancer (101). The same approach has
been used in RA in a study testing a new indication for the
anti-cancer drug camptothecin a Topoisomerase I inhibitor.
Camptothecin sterically stabilized micelles conjugated with VIP
(CPT-SSM-VIP) has been designed to be delivered in specific
cell types, such as synoviocites, T-cells and macrophages, where
VPAC2 are over-expressed. This approach of actively targeting
long circulating micelles to the effector cells in RA joints
improved the efficacy of the drug and reduced systemic toxicity.
They reported that a single, subcutaneous injection of low-dose
camptothecin preparation alleviated joint inflammation in the
CIA model (102).
Regarding the strategy of nanoparticles developed for VIP as
a drug, recently the beneficial effects in the CIA murine model
have been reported by targeting low doses of VIP self-associated
with sterically stabilizedmicelles (SSMs) [(18, 19); Figure 1]. This
spontaneous interaction of VIP with SSM protects the peptide
from enzymatic degradation or inactivation in biological fluids
and prolongs circulation half-life. The small size of the VIP
particles (∼15 nm) prevents the nanoparticle from extravasating
through undamaged blood vessel walls abolishing vasorelaxation
and also carrying the particles to the sites with “permeable”
vasculature, such as inflamed tissues. While the authors suggest
that the components of VIP-SSM formulation have been used for
humans in marketed pharmaceutical products such as InvicorpR
and DoxilR, there are still problems to be solved regarding their
biodistribution, not only in the joints but also in the kidney and
liver (18).
In a recent study, this strategy confirmed that VIP-SSM
prevented and ameliorated severe inflammation related to
DSS-induced colitis, in a murine model of inflammatory
bowel disease. The treatment reversed the augmented pro-
inflammatory cytokine expression (IL-1β, CXCL1, CXCL2, and
CCL3), injured distal colonic histology, and reduced tight
junction (occludin expression) and ion transporter protein
expression associated with severe DSS colitis [(20); Figure 1].
The negative side of the current systemic RA treatments,
previously described, is the appearance of side effects. These are
generated by the toxicity associated with long-term treatments
and large doses that these drugs induce. To evade the off-target
toxicity of these drugs, a potential solution is the development
of joint-targeting drug delivery. The VIP-based strategy for
targeted RA still requires more research, and the resolution of
different problems, being one of them, to guarantee their arrival
exclusively to the joint.
Tracing the Potential of the VIP/VPAC
Receptors Axis as Biomarker
The early recognition and treatment of RA is hampered by its
heterogeneous nature. Current strategies for the management
of RA focus on identification and intervention in the “window
of opportunity,” the initial period of the disease in which joint
damage can be avoided through early and continuous therapy to
slow or stop the evolution of the disease (21, 103) as discussed
above. Thus, new challenges emerge in the search of prognostic
biomarkers to guide personalized treatment decisions.
Given these concerns, we have recently described the utility
of measuring VIP as a clinical biomarker in patients with early
arthritis (EA) (104). We demonstrate an association between VIP
serum levels and genetic variants in the VIP gene and describe
certain combinations of genotypes of these variants associated
with a greater intensity of treatment in our patients (21, 23).
These results highlight the relevance of the detection of VIP
genetic variants that allows the stratification of patients as a
complementary tool for supporting therapeutic decisions.
New evidence underscores the importance of the
VIP/receptors axis through the association of expression
levels of VPAC receptors with the clinical status of EA patients
(22). In a population of early arthritis EA patients, we evaluated
the expression of VPAC1 and VPAC2 in PBMCs during the
clinical follow-up (22). We reported that the expression of
VPAC1 increased significantly reaching the highest values after 2
years of follow-up, whereas VPAC2 expression decreased. Thus,
we described an inverse correlation between the expressions of
both receptors during the course of EA suggesting a possible
dynamic regulation in the different stages of the disease probably
as a compensatory mechanism (22).
The assessment of the activity of RA by several variables
is of crucial importance in daily clinical practice with the aim
of reducing inflammation and achieving remission. Elevated
levels of IL-6 in the serum of patients are considered a marker
of inflammation correlating directly to the clinical activity of
the disease and to joint destruction (105, 106). Interestingly, a
negative correlation has been described between the levels of
VPAC1 and IL-6, parallel to the positive association between the
levels of this cytokine and the VPAC2 receptor (22). This result
points to the role of the low level of expression of VPAC1 as a
marker of a more intense inflammatory process.
What is truly remarkable, however, is the relationship between
VPAC1 levels and the activity of the disease measured by the
disease activity score (DAS), DAS 28 index. Thus, when we
clustered EA patients into 3 sub-groups considering their DAS28
levels (remission-low, moderate, and high disease activity), we
found that patients with moderate/high activity of the disease
show the lowest levels of VPAC1, while patients in remission
have higher levels of this receptor. In addition, the expression
of VPAC1 makes it possible to distinguish groups of patients
with different degrees of disease activity that could serve as an
indicator of disease activity in RA (22).
In light of the above, the evaluation of the global activity
of the disease by the patient has been gaining relevance in the
determination of the outcome of RA showing a high predictive
value (107, 108) and allowing pathways to improvement, not only
in terms of the traditional objectives of decreased activity but
also in terms of patient satisfaction (109). In this context, it has
been demonstrated that lower levels of VPAC1 expression are
associated with patient-reported impairment correlating better
than other serum biomarkers of activity used in clinical practice,
such as the erythrocyte sedimentation rate [(22); Figure 1].
The American College of Rheumatology/European
League against Rheumatism (110), the European League
against Rheumatism (111) and the international working
group to address the objectives (112), recommend frequent
evaluation of disease activity in order to reduce, or better
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eliminate, inflammation (113). Therefore, the identification
of new biological markers, which reflect the underlying
pathophysiological processes associated with the clinical activity
of RA, are the target of numerous investigations.
In this sense and given the ability of VIP to regulate the
intensity of the inflammatory process and the immune response,
the expression of VPAC1 in RA, associated with the activity of the
disease, would reflect the patient’s clinical status and complement
other serum biomarkers of activity used, such as ESR and C-
reactive protein (CRP) (114) which are biased by factors such as
the gender and the disease duration (115).
In summary, we can conclude that the VIP/VPAC axis
represents a promising biomarker in RA because it could allow
patients to be stratified with the purpose of guiding personalized
treatment decisions.
CONCLUDING REMARKS
The experimental data explained above demonstrate the
VIP/VPAC receptor axis as an important endogenous mediator
involved in anti-inflammatory and autoimmunity responses in
RA. In recent years, sufficient information has been generated
related to the VIP/VPAC receptor axis to yield an effective
translation of these preclinical studies. The research area that
seems most advanced for clinical application is its role as a
biomarker. Important advances are beingmade toward obtaining
the means to ensure that the determination of biomarkers allows
an accurate prognosis of the onset as well as the valuation of
severity of RA. According to the information reported, it may be
that in this scenario, the VIP/VPAC axis occupies an important
place as a biomarker of this disease. However, for its clinical
application to become a reality, more research is needed. The
involvement of genetic, epigenetic and miRNAs in the expression
of VPAC receptors, and validation in several cohorts of patients,
among other issues, are important challenges that must be
addressed in future research.
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